https://www.biospace.com/article/j-and-j-s-tremfya-shows-extended-success-in-treating-plaque-psoriasis/
J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
News
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-Phase-3-Psoriasis-Study-Meets-All-Endpoints-Achieving-Significantly-Greater-Efficacy-Versus-Placebo-and-Ustekinumab
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study
https://www.mdlinx.com/journal-summaries/prospect-psoriasis-real-life-secukinumab-transition/2019/09/26/7580185/?spec=dermatology&rcid=38
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study
Can CBD Relieve Psoriasis Symptoms? Here’s What Doctors Are Saying
https://www.health.com/condition/psoriasis/cbd-for-psoriasis
Can CBD Relieve Psoriasis Symptoms? Here’s What Doctors Are Saying
Lilly, AbbVie unveil new data for psoriasis treatment at global meet
http://www.koreabiomed.com/news/articleView.html?idxno=5925
Lilly, AbbVie unveil new data for psoriasis treatment at global meet
Shares of Bausch Health, formerly Valeant, rise 3% on FDA approval of psoriasis treatment
https://www.cnbc.com/2019/04/25/shares-of-bausch-health-formerly-known-as-valeant-rise-3percent-on-fda-approval-for-psoriasis-treatment.html
FDA Approves Combination Lotion [Duobrii] for Plaque Psoriasis
https://www.mdmag.com/medical-news/fda-approves-combination-lotion-plaque-psoriasis
Portfolio in the U.S. with FDA Approval of SKYRIZI (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
https://www.prnewswire.com/news-releases/abbvie-expands-immunology-portfolio-in-the-us-with-fda-approval-of-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis-300836934.html
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
https://www.newswire.ca/news-releases/health-canada-approves-skyrizi-tm-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-852708327.html
Novartis first-in-class Cosentyx (secukinumab) approved in China for psoriasis patients
https://www.globenewswire.com/news-release/2019/04/02/1794808/0/en/Novartis-first-in-class-Cosentyx-approved-in-China-for-psoriasis-patients.html
First global regulatory approval of SKYRIZI (risankizumab) in Japan
https://www.biospectrumasia.com/news/28/13108/abbvie-gets-the-first-global-regulatory-approval-of-skyrizi-in-japan.html
AbbVie Announces First Regulatory Approval of SKYRIZI (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis
https://www.prnewswire.com/news-releases/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan-300818288.html
Health Canada Approves CIMZIA® (certolizumab pegol) for Moderate-to-Severe Psoriasis
https://www.newswire.ca/news-releases/health-canada-approves-cimzia-r-certolizumab-pegol-for-moderate-to-severe-psoriasis-883050362.html
DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
https://www.biospace.com/article/releases/durect-announces-patient-dosing-in-phase-2a-proof-of-concept-clinical-trial-of-topical-dur-928-in-patients-with-mild-to-moderate-plaque-psoriasis/
http://investors.durect.com/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=2391958
Secukinumab showed promise in treating patients with palmoplantar pustular psoriasis (PPP), according to clinical trial results published in the Journal of the American Academy of Dermatology.
Examining the Potential Benefits of Secukinumab in Palmoplantar Pustular Psoriasis Treatment
Examining the Potential Benefits of Secukinumab in Palmoplantar Pustular Psoriasis Treatment
Study Demonstrates Positive Results for Psoriasis Patients Treating with the Clarify Home Light Therapy System
https://venturebeat.com/2019/03/13/study-demonstrates-positive-results-for-psoriasis-patients-treating-with-the-clarify-home-light-therapy-system/
Most Systemic Therapies Safe and Effective for the Treatment of Psoriatic Arthritis
A recent phase 2 study demonstrated the efficacy and tolerability of BMS-986165, a novel TYK2-Inhibitor, in patients with moderate to severe plaque psoriasis. Based on this data, BMS-986165 is a promising future therapeutic agent for patients with plaque psoriasis.
https://www.the-dermatologist.com/article/novel-tyk2-inhibitor-treatment-plaque-psoriasis
Novel TYK2-Inhibitor for the Treatment of Plaque Psoriasis
Promising treatments in the pipeline for psoriasis, according to American Academy of Dermatology Spring Meeting 2019
https://www.dermatologytimes.com/article/promising-treatments-pipeline-psoriasis
FDA Approves Self-Injection Guselkumab for Plaque Psoriasis
https://www.mdmag.com/medical-news/fda-approves-selfinjection-guselkumab-for-plaque-psoriasis
New psoriasis treatment guidelines released this month by the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) outline the use of biologics in treating and managing psoriasis.
https://www.centerforbiosimilars.com/news/psoriasis-guideline-antitnf-biosimilars-can-be-considered-therapeutically-interchangeable-with-references
Secukinumab (Cosentyx, Novartis) improved quality of life in patients with moderate-to-severe plaque psoriasis (PsO), according to data from a pooled analysis of 4 phase 3 clinical trials.
https://www.specialtypharmacytimes.com/news/secukinumab-demonstrates-quality-of-life-improvements-in-psoriasis-patients
